DocMorris in the news

DocMorris stock increased by 2.2 percent to 12.76 CHF, trading 6.74 percent below its 52-week high, following a reported loss per share of -1.06 CHF and stable revenue for the last quarter.

DocMorris faced a seizure of funds, as reported by the American Bankers Association and FactSet Research Systems Inc.

DocMorris shares fell by 1.4 percent to 12.31 CHF, with analysts predicting a loss of -1.660 CHF per share in 2026.

DocMorris's stock price increased by 3.5% to 12.92 CHF on SIX SX, with analysts forecasting a loss of -1.660 CHF per share for the company in 2026.

DocMorris stock experienced a 2.3% decline to 12.52 CHF on SIX SX, with past quarterly results showing a loss per share of -1.06 CHF and revenue of 260.83 million CHF, and analysts projecting a 2026 loss of -1.660 CHF per share.

DocMorris had funds seized in the Netherlands following a legal dispute with German pharmacists regarding advertising and discount practices.

DocMorris shares fell by 2.0 percent to CHF 12.55, with analysts forecasting a loss per share of -CHF 1.660 for 2026.

DocMorris shares declined by 3.7% to 12.33 CHF, with negative earnings per share of -1.06 CHF and flat revenue for Q2 2025.

DocMorris's Dutch accounts were garnished by the North Rhine Chamber of Pharmacists due to millions in unpaid German fines for prohibited advertising campaigns.

A Dutch court upheld the seizure of DocMorris's accounts to collect unpaid German court fines for prohibited price advertising.

DocMorris faced garnishment of its Dutch bank accounts to recover 210,000 euros in regulatory fines for prohibited promotional pricing, a legal action challenged unsuccessfully by the company.

The document details the revenue per share for DocMorris Ltd.

DocMorris stock rose by 1.5% to 12.75 CHF, trading above its 52-week low but below its 52-week high, with analysts expecting a loss per share for 2026.

DocMorris stock gained 3.5% on the SIX SX exchange, reaching 13.00 CHF, while analysts project a loss for the company in 2026.

DocMorris stock experienced a 4.0% decline to 12.88 CHF in SIX SX trading, with analysts forecasting a loss of -1.660 CHF per share for 2026.

DocMorris shares dropped 3.1% to CHF 13.00 on Thursday morning, trading 4.77% below its 52-week high, while analysts predict a loss for 2026.

DocMorris stock fell 3.6% to 12.93 CHF, with a loss per share of -1.06 CHF in Q2 2025, and analysts forecast a -1.660 CHF loss per share in 2026.

The Swiss Market Index declined by 1.5%, influenced by rising oil prices and interest rates, while US markets also saw drops due to economic data, although some tech stocks like Accenture and Micron performed well, but DocMorris stock fell by 4.1%.

DocMorris' shares saw significant gains throughout the day, fueled by positive market sentiment and an "Overweight" rating from an analyst firm.

DocMorris shares surged, hitting a 52-week high, despite reported losses and stagnant revenue for the last quarter.